Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Thursday. The stock had previously closed at $41.99, but opened at $38.10. Zealand Pharma A/S shares last traded at $38.10, with a volume of 1,000 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ZLDPF shares. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Zealand Pharma A/S presently has an average rating of “Hold”.

Zealand Pharma A/S Trading Down 12.7%

The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of 6.32 and a beta of 0.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. The business has a fifty day moving average price of $46.91 and a 200 day moving average price of $46.38.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.